Biotech IPO Tracker 2026
This page tracks biotech and biopharma IPOs in 2026, including therapeutic area, lead asset, stage at IPO, pricing date, offer price, gross proceeds, approximate market capitalization at listing, and aftermarket performance.
It is built for biotech investors, bankers, founders, and BD teams who want a fast read on how the IPO window is developing — which stories are getting out, which are holding up, and what that says about risk appetite across the financing market.
BioBucks updates this tracker as new IPOs price. The daily newsletter then adds the read-through: new filings, launches, pricings, discounts, upsizes, and aftermarket movers — plus what they mean for the broader biotech capital-markets backdrop.
Last updated:
17 May 2026
Get the daily biotech financing read-through (free)
Track IPO filings, launches, pricings, discounts, upsizes, and aftermarket movers in a daily 5-minute email. The tracker shows the data; BioBucks tells you what matters.
Read by 2,000+ VC, bankers, BD&L, and public biotech investors. No spam. Unsubscribe anytime.
2026 biotech IPO market snapshot
- 12 priced biotech IPOs are tracked here so far in 2026, with the latest reopening wave led by Avalyn Pharma, Seaport Therapeutics, Hemab Therapeutics, and Odyssey Therapeutics.
- Largest deal so far: Kailera Therapeutics at $718.8M gross proceeds, including full exercise of the underwriters’ option; across the current cohort, tracked IPO gross proceeds now total roughly $4.0B.
- Best aftermarket performer: Veradermics, which remains the standout winner at roughly +487% from issue price at the latest scoreboard refresh — a reminder that a clean, commercial aesthetic-derm story can still rip even when the broader class is mixed.
- The more sobering read: among the 12 names with live aftermarket data on this page, four trade below issue and Generate is roughly flat; Odyssey, Seaport, Agomab, and Eikon are below issue, while Avalyn, Hemab, SpyGlass, Kailera, Alamar, Aktis, and Veradermics are above issue.
- Bifurcation remains the right frame: investor demand is still rewarding differentiated, later-stage, and cleaner commercial stories, but the class is no longer trading up uniformly after pricing.
- Window read-through: 2026 now looks open, but still discriminating — the market can absorb multiple $250M+ biotech IPOs in quick succession, but aftermarket support is still being rationed.
IPOs